CN109200203A - Chinese medicine composition and its application for treating primary osteoporosis - Google Patents
Chinese medicine composition and its application for treating primary osteoporosis Download PDFInfo
- Publication number
- CN109200203A CN109200203A CN201811405280.9A CN201811405280A CN109200203A CN 109200203 A CN109200203 A CN 109200203A CN 201811405280 A CN201811405280 A CN 201811405280A CN 109200203 A CN109200203 A CN 109200203A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- osteoporosis
- primary osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of Chinese medicines, a kind of Chinese medicine composition for treating primary osteoporosis is provided, is grouped as by the group of following parts by weight: 5-15 parts of deer horn glue, 5-12 parts of Herba Cistanches, 5-15 parts of Rehmannia glutinosa, 5-12 parts of radix cyathulae, 5-12 parts of Semen Cuscutae, 5-12 parts of pawpaw, 5-12 parts of Cortex Eucommiae, 5-12 parts of Rhizoma Gastrodiae.Chinese medicine composition of the invention can be obviously improved the symptom, sign, skeleton metabolism of Osteoporosis, and bone mineral density can be improved, clinical efficacy is definite, not only there is benign adjustment effect to improvement and alleviation primary osteoporosis, and take nothing for a long time and have no adverse reaction.The present invention also provides the preparation method and applications of the Chinese medicine composition.
Description
Technical field
The invention belongs to the field of Chinese medicines more particularly to a kind of Chinese medicine composition for treating primary osteoporosis and its answer
With.
Background technique
Primary osteoporosis is the common disease of orthopaedics, is apt to occur in postmenopausal women and elderly men, is with bone strength
Decline, the disease of skeletal system that risk of bone fracture increase is characterized.National Institutes of Health is defined as with bone within 2001
The skeletal diseases that intensity decline and risk of bone fracture increase are characterized.Especially postmenopausal women is easily involved, and is to seriously endanger women
The disease of health.The risk (40%) that osteoporotic fracture occurs in all one's life for women is higher than breast cancer, carcinoma of endometrium and ovum
The summation of nest cancer is one of the main reason for gerontal patient disables and is lethal.As aging of population number of patients increases year by year,
WHO is classified as one of three big diseases of old people.Osteoporotic fracture and its complication drastically influence the life matter of the middle-aged and the old
Amount, becomes global one of public health problem.Therefore, effective prevention and treatment of osteoporosis has become when business
It is anxious.This disease is mainly shown as whole body ostalgia, deformation of spinal column, or even the consequences such as osteoporotic fracture occur.According to primary bone
The clinical manifestation of matter osteoporosis is belonged to " atrophic debility of bones " of Chinese medicine, " heumatism ", " bone is withered ", " bone exhaustion ", " bone erosion " etc. more now
Scope, mainly since kidney essence deficiency, bone lose the chronic degenerative diseases of whole body bone caused by nourishing.Kidney essence deficiency, marrow
Loss, bone dystrophy are the key points of developing osteoporosis.Therefore, kidney deficiency marrow subtract be postmenopausal osteoporosis occur root
This reason plays important regulating and controlling effect to the development of its course of disease.
Summary of the invention
It is an object of the invention to overcoming above-mentioned the deficiencies in the prior art, a kind of primary osteoporosis for the treatment of is provided
Chinese medicine composition.
The invention is realized in this way a kind of Chinese medicine composition for treating primary osteoporosis, by following parts by weight
Several groups are grouped as: 5-15 parts of deer horn glue, 5-12 parts of Herba Cistanches, 5-15 parts of Rehmannia glutinosa, 5-12 parts of radix cyathulae, Semen Cuscutae 5-12
Part, 5-12 parts of pawpaw, 5-12 parts of Cortex Eucommiae, 5-12 parts of Rhizoma Gastrodiae.
Preferably, Chinese medicine composition of the invention is grouped as by the group of following parts by weight: 15 parts of deer horn glue, Herba Cistanches 10
Part, 15 parts of Rehmannia glutinosa, 10 parts of radix cyathulae, 10 parts of Semen Cuscutae, 10 parts of pawpaw, 10 parts of Cortex Eucommiae, 10 parts of Rhizoma Gastrodiae.
Specifically, the Chinese medicine composition is decoction, powder, pill, capsule or granule.
The present invention also provides application of the foregoing Chinese medicine composition in treatment primary osteoporosis.
Chinese medicine composition of the invention can be obviously improved the symptom, sign, bone metabolism of Osteoporosis
Index, and bone mineral density can be improved, clinical efficacy is definite, not only has to improvement and alleviation primary osteoporosis benign
Adjustment effect, and take for a long time without having no adverse reaction.
Specific embodiment
A kind of Chinese medicine composition for treating primary osteoporosis provided by the invention, by the component of following parts by weight
Composition: 5-15 parts of deer horn glue, 5-12 parts of Herba Cistanches, 5-15 parts of Rehmannia glutinosa, 5-12 parts of radix cyathulae, 5-12 parts of Semen Cuscutae, pawpaw 5-
12 parts, 5-12 parts of Cortex Eucommiae, 5-12 parts of Rhizoma Gastrodiae.
Preferably, Chinese medicine composition of the invention is grouped as by the group of following parts by weight: 10-15 parts of deer horn glue, meat desert
10-12 parts of Rong, 10-15 parts of Rehmannia glutinosa, 10-12 parts of radix cyathulae, 10-12 parts of Semen Cuscutae, 10-12 parts of pawpaw, 10-12 parts of Cortex Eucommiae,
10-12 parts of Rhizoma Gastrodiae.
The pharmacology and effect of Chinese medicine composition each component of the invention are as follows:
Deer horn glue: warm nourishing liver and kidney, replenishing blood and vital energy, production of sperm marrow；
Herba Cistanches: kidney-replenishing, benefiting essence-blood；
Rehmannia glutinosa: enrich blood moist, beneficial to spirit and marrow；
Radix cyathulae: nourishing liver and kidney, strengthening the bones and muscles, blood circulation；
Semen Cuscutae: nourishing liver and kidney, benefiting quintessence；
Pawpaw: relaxing tendons and activating collaterals, removing dampness to restore normal functioning of the stomach；
Cortex Eucommiae: nourishing liver and kidney, strengthening the bones and muscles；
Rhizoma Gastrodiae: breath liver wind, and Pinggan Yang, dispelling wind and removing obstruction in the meridians.
Above-mentioned kinds of traditional Chinese medicines is followed to the principles of formulating prescriptions of Chinese medicine " monarch ", wherein deer horn glue, Herba Cistanches, Rehmannia glutinosa are
Monarch drug in a prescription, for kidney tonifying, essence replenishing, mends marrow fill bone must with medicine；Radix achyranthis bidentatae, Cortex Eucommiae, Semen Cuscutae, Rhizoma Gastrodiae be ministerial drug, with enhance nourishing liver and kidney,
The effect of strong marrow；Pawpaw is adjuvant, and pawpaw enters liver with strengthening tendons.All medicines share plays the function of " kidney tonifying marrow facilitating, strengthening muscles and bones " altogether
Effect has good preventive and therapeutic effect to primary osteoporosis.
Following embodiment further illustrates the contents of the present invention, but should not be construed as limiting the invention.
Embodiment 1
A kind of Chinese medicine composition for treating primary osteoporosis that the embodiment of the present invention 1 provides, by following parts by weight
Several groups are grouped as: 5 parts of deer horn glue, 5 parts of Herba Cistanches, 5 parts of Rehmannia glutinosa, 5 parts of radix cyathulae, 5 parts of Semen Cuscutae, 5 parts of pawpaw, Cortex Eucommiae 5
Part, 5 parts of Rhizoma Gastrodiae.
The preparation method of the Chinese medicine composition of the embodiment of the present invention 1, includes the following steps:
(1) Herba Cistanches of above-mentioned parts by weight, Rehmannia glutinosa, radix cyathulae, Semen Cuscutae, pawpaw, Cortex Eucommiae and Rhizoma Gastrodiae are mixed equal
It is even to obtain mixture, the mixture and water are mixed according to the ratio of weight ratio 1: 5, impregnated 30 minutes in water；
(2) mixture in step (1) is decocted together with water and the second filtrate and filter residue is obtained by filtration after sixty minutes；
(3) gained filter residue in step (2) and water are mixed according to the ratio of weight ratio 1: 4, then decocts 60 minutes, then mistake
Filter obtains third filtrate and filter residue, and the second filtrate is mixed with third filtrate, obtains the 4th filtrate；
(4) the deer horn glue molten of above-mentioned parts by weight is entered in the 4th filtrate, obtains the decoction of drug.
Embodiment 2
A kind of Chinese medicine composition for treating primary osteoporosis that the embodiment of the present invention 2 provides, by following parts by weight
Several groups are grouped as: 10 parts of deer horn glue, 8 parts of Herba Cistanches, 10 parts of Rehmannia glutinosa, 9 parts of radix cyathulae, 9 parts of Semen Cuscutae, 8 parts of pawpaw, Cortex Eucommiae
11 parts, 8 parts of Rhizoma Gastrodiae.
The preparation method is the same as that of Example 1 for the Chinese medicine composition of the embodiment of the present invention 2.
Embodiment 3
A kind of Chinese medicine composition for treating primary osteoporosis that the embodiment of the present invention 3 provides, by following parts by weight
Several groups are grouped as: 15 parts of deer horn glue, 12 parts of Herba Cistanches, 15 parts of Rehmannia glutinosa, 12 parts of radix cyathulae, 12 parts of Semen Cuscutae, 12 parts of pawpaw,
12 parts of Cortex Eucommiae, 12 parts of Rhizoma Gastrodiae.
The preparation method is the same as that of Example 1 for the Chinese medicine composition of the embodiment of the present invention 3.
Embodiment 4
A kind of Chinese medicine composition for treating primary osteoporosis that the embodiment of the present invention 4 provides, by following parts by weight
Several groups are grouped as: 6 parts of deer horn glue, 7 parts of Herba Cistanches, 6 parts of Rehmannia glutinosa, 8 parts of radix cyathulae, 8 parts of Semen Cuscutae, 7 parts of pawpaw, Cortex Eucommiae 12
Part, 10 parts of Rhizoma Gastrodiae.
The preparation method is the same as that of Example 1 for the Chinese medicine composition of the embodiment of the present invention 4.
Embodiment 5
A kind of Chinese medicine composition for treating primary osteoporosis that the embodiment of the present invention 5 provides, by following parts by weight
Several groups are grouped as: 9 parts of deer horn glue, 10 parts of Herba Cistanches, 8 parts of Rehmannia glutinosa, 9 parts of radix cyathulae, 10 parts of Semen Cuscutae, 11 parts of pawpaw, Du
Secondary 7 parts, 8 parts of Rhizoma Gastrodiae.
The preparation method is the same as that of Example 1 for the Chinese medicine composition of the embodiment of the present invention 5.
Embodiment 6
A kind of Chinese medicine composition for treating primary osteoporosis that the embodiment of the present invention 6 provides, by following parts by weight
Several groups are grouped as: 10 parts of deer horn glue, 11 parts of Herba Cistanches, 9 parts of Rehmannia glutinosa, 10 parts of radix cyathulae, 12 parts of Semen Cuscutae, 10 parts of pawpaw,
9 parts of Cortex Eucommiae, 10 parts of Rhizoma Gastrodiae.
The preparation method is the same as that of Example 1 for the Chinese medicine composition of the embodiment of the present invention 6.
Embodiment 7
A kind of Chinese medicine composition for treating primary osteoporosis that the embodiment of the present invention 7 provides, by following parts by weight
Several groups are grouped as: 15 parts of deer horn glue, 10 parts of Herba Cistanches, 15 parts of Rehmannia glutinosa, 10 parts of radix cyathulae, 10 parts of Semen Cuscutae, 10 parts of pawpaw,
10 parts of Cortex Eucommiae, 10 parts of Rhizoma Gastrodiae.
The preparation method of the Chinese medicine composition of the embodiment of the present invention 7, includes the following steps:
(1) 10 parts of Herba Cistanches, 15 parts of Rehmannia glutinosa, 10 parts of radix cyathulae are impregnated 30 minutes in water；
(2) decocting 50 minutes again, take pan-fried juice, form the adhesive of water-soluble liquid；
(3) take again 15 parts of deer horn glue, 10 parts of Semen Cuscutae, 10 parts of pawpaw, 10 parts of Cortex Eucommiae, 10 parts of Rhizoma Gastrodiae break into fine powder, with step
Suddenly the adhesive mixing in (2), is made decoction pill in the method for pelletization of dripping.
Treat primary osteoporosis clinical observation research
For the therapeutic effect for showing drug of the present invention, Shenzhen in October, -2018 in June, 2016 is collected in this clinical observation research
The orthopaedics of the hospitals of traditional Chinese and western medicine of city be hospitalized, out-patient, standard compliant osteoporosis 40, according to Double-blind
Principle, be divided into two groups using computer random digits table, wherein intervention group 20, control group 20, two groups in the state of an illness, property
Not, age etc. is statistically analyzed no significant difference, is comparable.All patients for being included in research sign
Informed consent form, and through institute's Medical Ethics Committee examining testimony meet ethics relevant regulations.
Diagnostic criteria: the Western medicine diagnostic criteria, " Chinese formulated referring to WHO osteoporosis standard and Aged in China association
Osteoporosis suggests diagnostic criteria ", according to dual energy X-ray absorptiometry measuring instrument (Dual-energy X-ray
Absorptiometry measurement instrument, DXA) measurement waist 1 to 4 centrum of waist (L1-4) normotopia bone density
(BMD), diagnostic criteria is recommended according to WHO, value≤- 2.5 T is determined as osteoporosis, tcm diagnosis standard is referring to " Chinese medicine
Drugs in Therapy osteoporosis clinical observation guideline ".
It is included in standard: the age 50-70 years old, Osteoporosis；Without great organic disease and psychiatric
Disease；There is lumbago；Without osteosporosis resistant medicament systematic treating.
Exclusion criteria: multi viscera lesion patient, the heart, lung, liver, kidney, thyroid gland etc. Disease and serious heart and brain
The patient of vascular diseases etc.；The diseases such as serious liver and kidney dysfunction, coagulation disorders, digestive tract ulcer；It is used in nearly half a year
Influence bone metabolism drug, such as vitamin D, calcium preparation, estrogen, Diphosphonate, fluoride preparation；Psychiatric patient；Not according to
Provide medication, the not congruent influence result judgement person of data.
Treatment method: patient is divided into control group and treatment group according to random principle, it is odd that control group gives oral calcium that
D, Alfacalcidol soft capsule；Oral Caltrate D is given by treatment group, on the basis of Alfacalcidol soft capsule, takes orally the present invention
Chinese medicine composition (nourshing kidney strong bone side), Chinese materia medica preparation come from Drug Manufacturing Room, daily administration 2 times, 250mL are administered every time, cooperation is taken
Alfacalcidol soft capsule (being administered once daily, 0.5 μ g is administered every time) and Caltrate D (are administered once daily, are administered every time
600mg), observing time 4 weeks.
Clinical efficacy: evaluation criterion develops and publishes " new Chinese medicine clinic referring to Ministry of Health of the People's Republic of China in 1997
Study guideline " it formulates.Effective: lumbar vertebrae pain symptom completely disappears, and bone density inspection shows that bone density increases.It is effective: waist
Ridge pain symptom is relieved, and bone density checks bone density without increase.It is invalid: to compare various aspects without improvement with before treatment.
Pain measurement: VAS scoring, i.e. pain visual imitation assessment: the horizontal line of standardized 10cm on paper, the one of horizontal line
End is 0, is indicated painless；The other end is 10, indicates severe pain；Middle section indicates different degrees of pain.
Bone densitometry: 1~4 bone density of patient's normotopia lumbar vertebrae is measured using dual energy X-ray absorptiometry measuring instrument before and after treatment.
Skeleton metabolism measurement: two groups of patients will terminate for one day with this research before administration under fasting state
Afterwards second day, under early morning fasting state, 5mL venous blood is acquired, takes out serum, sets -70 DEG C of refrigerators storages until measurement.It is enzyme-linked
Immuno absorbence (ELISA) method detects serum Bone markers β-type i collagen c-terminal peptides (β-CTx) and total type i collagen amino
End extends peptide (T-PINP).
Safety evaluation: two groups of patients equal promoting circulation of blood routine, electrocardiogram and hepatic and renal function inspection before and after treatment.
Statistical analysis: being handled using 22.0 statistics software of SPSS, in continuous data group before and after treatment and between group
Mean compares to be examined with t, and enumeration data uses non-parametric test, indicates that difference is statistically significant with P < 0.05.
Clinical efficacy comparison after two groups of patients intervene: statistical test calculates the clinical efficacy of two groups of patients, two groups of treatments
The results show that treatment group and control group total effective rate are 100.00%, 80.00% respectively, satisfaction is obtained after two groups of treatments
Curative effect；Two groups of curative effects are statistically analyzed P < 0.05, statistically significant, it is seen that two groups of therapeutic effects there are statistical difference,
The curative effect for the treatment of group is preferable.
Note: total effective rate=obvious effective rate+effective percentage；Comparison among groups are examined using Mann-whitney U.
Two groups of patient's patients before and after intervention VAS scorings are compared: patient VAS scoring (P < can be substantially reduced after two groups of case interventions
0.05) compare for two groups, and after intervening, scoring reduces obvious after treatment group's treatment, is better than control group (P < 0.05), i.e. treatment group
It can be obviously improved pain, difference has statistical significance.
Note: compared with before intervening with this group,**P < 0.05；Two comparison among groups after intervention,▲P < 0.05.
Two groups of patient's patients before and after intervention bone densities (BMD) are compared: can significantly improve waist before relatively intervening with group after two groups of interventions
Vertebra BMD (g/cm2), especially treatment group (P < 0.05).But treatment group's no statistical difference compared with the control group after intervention
Meaning, but have raised trend.This may with intervention time is still short a relationship, consider in next research, extend dry
The pre- time observes the influence to bone density.
Note: compared with before intervening with this group,**P < 0.05；Two comparison among groups after intervention,▲P < 0.05.
The comparison of two groups of patient patients before and after intervention β-CTx, T-PINP: two groups of cases can be obvious before relatively intervening with group after intervening
Reduce patient β-CTx expression (P < 0.05), and after intervening two groups compare, β-CTx value reduces obvious after treatment group's treatment, is better than
Control group (P < 0.05), difference have statistical significance.T-PINP expression (P < 0.05) can be significantly improved after two groups of interventions.
But treatment group's no significant difference compared with the control group after intervening, but have raised trend, when this may be with intervening
Between it is still short have a relationship, consider in next research, extend intervention time to observe the influence to bone density.
Note: compared with before intervening with this group,**P < 0.05；Two comparison among groups after intervention,▲P < 0.05.
Safety indexes: two groups of follow-up of patients the result shows that, unreported hepatic and renal function, electrocardiogram in two groups of patients treatment
Etc. indexs exception, have no the adverse reactions such as medicamentosus diarrhea, abdominal pain, Chinese medicine compound prescription of the invention as a result prompted to have preferable peace
Quan Xing, long-term use have no adverse reaction.
Clinical observation result shows that Chinese medicine composition of the invention can be obviously improved Osteoporosis
Symptom, sign, skeleton metabolism, and bone mineral density can be improved, clinical efficacy is definite, not only to improvement and alleviation primary bone
Matter osteoporosis has benign adjustment effect, and takes nothing for a long time and have no adverse reaction.
Claims (4)
1. a kind of Chinese medicine composition for treating primary osteoporosis, which is characterized in that be grouped by the group of following parts by weight
At: 5-15 parts of deer horn glue, 5-12 parts of Herba Cistanches, 5-15 parts of Rehmannia glutinosa, 5-12 parts of radix cyathulae, 5-12 parts of Semen Cuscutae, pawpaw 5-12
Part, 5-12 parts of Cortex Eucommiae, 5-12 parts of Rhizoma Gastrodiae.
2. Chinese medicine composition as described in claim 1, which is characterized in that be grouped as by the group of following parts by weight: deer horn glue
15 parts, 10 parts of Herba Cistanches, 15 parts of Rehmannia glutinosa, 10 parts of radix cyathulae, 10 parts of Semen Cuscutae, 10 parts of pawpaw, 10 parts of Cortex Eucommiae, 10 parts of Rhizoma Gastrodiae.
3. Chinese medicine composition as described in claim 1, which is characterized in that the Chinese medicine composition be decoction, powder, pill,
Capsule or granule.
4. a kind of application of Chinese medicine composition as described in claims 1 or 2 or 3 in treatment primary osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811405280.9A CN109200203A (en) | 2018-11-22 | 2018-11-22 | Chinese medicine composition and its application for treating primary osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811405280.9A CN109200203A (en) | 2018-11-22 | 2018-11-22 | Chinese medicine composition and its application for treating primary osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109200203A true CN109200203A (en) | 2019-01-15 |
Family
ID=64994135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811405280.9A Pending CN109200203A (en) | 2018-11-22 | 2018-11-22 | Chinese medicine composition and its application for treating primary osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109200203A (en) |
-
2018
- 2018-11-22 CN CN201811405280.9A patent/CN109200203A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 卞玉群: "补肾法治疗原发性骨质疏松症的理论与实验研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 顿宝生: "《中医用药精华》", 31 July 1999, 世界图书出版西安公司 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101926878B (en) | Chinese medicinal composition for treating osteoarthritis and preparation method thereof | |
| US8337910B2 (en) | Herbal formulation for the treatment of bone fractures and osseous defects | |
| CN106361947A (en) | Preparation method of traditional Chinese medicine for treating osteoporosis | |
| CN109200203A (en) | Chinese medicine composition and its application for treating primary osteoporosis | |
| CN101904958B (en) | Oral medicinal composition for treating fracture | |
| CN103271961B (en) | Preparation for treating rheumatic bone diseases | |
| CN118384214B (en) | A traditional Chinese medicine composition for preventing and treating osteoporosis | |
| CN118384231B (en) | A traditional Chinese medicine composition for preventing and treating osteoporosis | |
| CN107260967A (en) | A kind of pharmaceutical composition for treating gout | |
| CN100546612C (en) | Application of Gukang Medicine in Preparation of Preparations for Treating Osteoarthritis and Osteoporosis | |
| CN114377063B (en) | Traditional Chinese medicine composition for treating delayed fracture healing | |
| CN114558088B (en) | Mongolian medicine compound for treating primary osteoporosis and application thereof | |
| CN105616503A (en) | Composition for improving renal functions and preventing bone and joint ageing | |
| CN114642704B (en) | Pharmaceutical composition, preparation and application for treating femoral head necrosis | |
| CN103656309B (en) | A fracture/bone fracture healing auxiliary pharmaceutical composition | |
| CN104161936B (en) | A kind of Chinese medicine composition of prevention and treatment postmenopausal osteoporosiss and preparation method thereof | |
| CN1313120C (en) | Application of ciliate bugle herb piece in preparing medicine for treating scapulohumeral periarthritis | |
| CN109395008A (en) | Chinese medicine composition and its application for treating osteoporosis | |
| CN119633090A (en) | A Mongolian medicine compound for treating brittle fractures and its application | |
| CN1168472C (en) | Chinese medicine prepn for treating lupus erythematosus | |
| CN1879748A (en) | A group of compound Chinese medicinal oral preparation for treating osteoporosis and preparation method thererof | |
| CN105641191A (en) | Orally-taken medicine for treating fracture and soft tissue contusion at preliminary stage | |
| CN106266351A (en) | One is used for treating osteoporotic Chinese medicine formula | |
| CN104491292A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating osteoporosis | |
| CN119185437A (en) | Kidney-tonifying and blood-activating prescription for preventing and treating osteoporosis and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190115 |